Kornimate/medical-research-clean huggingface dataset:
reducing perioperative oxidative stress to prevent postoperative chronic pain following total knee arthroplasty

Conditions: Osteoarthritis, Knee; Total Knee Arthroplasty; Chronic Postsurgical Pain

Summary: this is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (os); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (glycine + n-acetyl-cysteine(glynac)) reduces oxidative stress and chronic post surgical pain (cpsp) in patients undergoing total knee arthroplasty (tka).

one of the most common surgical procedures performed in older adults is total knee arthroplasty (tka), with an estimated 1 million tkas performed annually in the united states. tka directly addresses the pathology underlying knee joint pain and mobility limitations resulting from osteoarthritis. for most patients, tka is effective for pain reduction and increasing function. however, a subgroup of 15-20% of tka patients report unsatisfactory long-term pain outcomes well after postsurgical healing has occurred despite technical success of the procedure. chronic postsurgical pain (cpsp) following tka has been reported to be worse than the preoperative pain in 7% of tka patients at up to 4-years. a potential biological mechanism is perioperative oxidative stress (os), the proposed project seeks to confirm the mechanistic role of os in post-tka cpsp and test the hypothesis that a perioperative intervention to reduce os may reduce risk for cpsp post-tka. this is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (os); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (glynac) reduces os and cpsp in patients undergoing total knee arthroplasty (tka).

Eligibility criteria:
inclusion criteria: * age 50 or older * intact cognitive status and ability to provide informed consent (based on cognitive screening with the mini mental state examination) * ability to read and write in english sufficiently to understand and complete study questionnaires * undergoing unilateral primary tka * medical diagnosis of osteoarthritis * past 24 hour worst numeric rating scale (nrs) pain of at least 4/10. exclusion criteria: * diagnosis of pre-existing neuropathy * untreated hypo/hyperthyroidism * untreated heart disease * alanine transaminase/aspartate transaminase \>2x upper-limit of normal range * serum creatinine \>1.5 mg/dl * pregnancy * complex regional pain syndrome (crps) diagnosis prior to undergoing tka * presence of lower extremity vascular disease, inflammatory or autoimmune disorders, or malignancy * presence of current clinically significant chronic pain conditions outside of the lower extremity ( daily pain for \>3 months and greater ≥3/10 in intensity or the focus of medical care) * presence of other medical conditions that in the opinion of the orthopedic surgeon co-investigators would make a patient's study participation unsafe
randomised trial of eutectic mixture of local anaesthetics cream and oral sucrose solution for venepuncture

Conditions: Pain

Summary: this randomized bicentric trial will investigate the efficacy of topical emla cream with oral sucrose solution compared to oral sucrose solution alone before venepuncture in preterm infants.

venepuncture is a painful procedure commonly performed in premature infants. nonpharmacological intervention (oral sucrose solution) can reduce neonatal pain. emla cream is an oil in water emulsion of an eutectic mixture of prilocaine and lignocaine; it is an local anesthetic cream. very few reports have looked at the efficacy of emla in preterm infants. this randomized bicentric trial will investigate the efficacy of topical emla cream with oral sucrose solution compared to oral sucrose solution alone before venepuncture in preterm infants.

Eligibility criteria:
inclusion criteria: * preterm infants (gestational age between 26 and 37 weeks) * programmed venepuncture * apgar score (m5)≥ 7 * enteral feeding * written parental consent exclusion criteria: * infant requiring oxygen * analgesia or sedation or drugs causing methaemoglobinaemia * congenital porphyria * g6pd deficit * multi organ failure * convulsion * dermatosis

Keywords: venepuncture pain emla cream oral sucrose solution premature infant premature infant admitted to the care baby unit were included in the study. programed venepuncture is performed with analgesia.
the effect of cervical muscle fatigue in neck proprioception and postural stability

Conditions: Muscle Fatigue

Summary: purpose: to investigate the effect of cervical muscle fatigue on neck proprioception and postural stability during cervical flexion. background: postural stability is the ability to maintain the body in equilibrium either at rest or in a steady state of motion . muscle fatigue is the diminished response of muscle to repeated stimulus. cervical proprioceptive inputs provide important somatosensory information influencing postural stability. hence, the investigators performed this study to evaluate the effect of experimentally induced fatigue on general cervical musculature on postural stability . hypotheses: this study will hypnotize that: 1. cervical flexor muscle fatigue will have a significant effect on neck proprioception 2. cervical muscle fatigue will have a significant effect on posture stability research question: will fatigue of cervical flexors have an effect on neck proprioception and postural stability?

the research methodology that will be used induction of fatigue using isometric neck flexor muscle endurance test (net): an isometric neck muscle endurance test (nme test) will be performed for the deep neck flexors (rectus capitus anterior, rectus capitus lateralis, longus capitus, longus colli) until exhaustion in all participants occurs. with the subject in hook lying position through chin retraction and head elevated from the couch. all the assessment measurements will be done before and just immediately after performing the cervical muscle fatigue then after 15 minutes of fatigue induction(fatigue recovery) a. measurement of neck proprioception using cervical joint position error test via overhead laser pointer b. measurement of postural stability using : 1. biodex balance system(limit of stability) to measure postural stability 2. multi-directional reach test

Eligibility criteria:
inclusion criteria: * having cervical range of motion 80 to 90 of flextion, 70 degree of extension, 20 to 45 degrees if lateral flextion, and 80 to 90 rotation to both sides. * having normaluscle test strength for cervical neck flexors according to group manual muscle test * body mass index ranging from 18.5 to 24.9 kg/m2 exclusion criteria: * any history of pathological truma to the cervical,thoracic or lumbar spine, upper extremity or rib cage. * surgical condition of the spine * having any orthopedic, musculoskeletal or neurological disorders around cervical region. * any vestibular impairment (e.g.vertigo) * spinal postural deformities as hyper kyphosis \&scoliosis

Keywords: fatigue ,deep neck flexor
evaluation of tolerance, efficacy and safety of an hydrolyzed formula in infants with ige/non-ige mediated cma.

Conditions: Cow's Milk Allergy

Summary: the aim of this interventional study is to assess the hypoallergenicity of a new formula in infants having a cow milk allergy (cma), whatever the type of cma, meaning in both ige-mediated and non-ige-mediated cma patients. this will be tested through a double-blind placebo controlled food challenge (dbpcfc) taking place over 2 or 3 separate days, in hospital. if the child tolerates the tested formula during the dbpcfc, he will be fed with the test formula during the second study phase. there will be monthly visit and parents will be asked to fill in diaries.

briefly, on two separate days, the placebo formula and the tehcf will be introduced at increasing doses under medical supervision, and appearance of allergic symptoms will be witnessed and recorded if any. the week after, and more particularly the 72 hours after each food challenge day, child's parents will be instructed to report to the investigator any delayed reaction that may occur. in case the tehcf induces an allergic reaction, the child's participation will be ended. otherwise, the child will enter the second study part, lasting 4 months and during which the usual formula taken by the child will be totally replaced by the tehcf.

Eligibility criteria:
inclusion criteria: * between 1 and 24 months old * having a cma proven in the last 3 months prior to inclusion * free of clinical allergic symptoms for at least one week (i.e., successfully fed an elimination diet) * whose parent(s)/legal guardian(s) signed the informed consent form. main exclusion criteria: * children mainly (\&gt;1 breastfeeding/day) or exclusively breastfed, with maternal willingness to continue breast-feeding * children with a mean formula intake lower than 250 ml/day * children with past anaphylactic reaction(s) * children with chronic (non acute) fpies -- children presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject, * children already participating in another clinical trial

Keywords: cma (cow's milk allergy) dbpcfc (double-blind placebo-controlled food challenge) fa (food allergy) ige (immunoglobulin e) ofc (oral food challenge)
prevention of heart failure induced by doxorubicin with early administration of dexrazoxane

Conditions: Degradation of Top2b and Top2a in Human by Dexrazoxane; Time Course and Degradation of Top2b in Human by Dexrazoxane; Effects of Dexrazoxane on Healthy Human

Summary: the purpose of this research study is to determine whether early administration of dexrazoxane prevents doxorubicin induced cardiotoxicity.

this is a study on volunteers to determine effective dose of dexrazoxane in degrading topoisomerase 2 b in human blood samples. each participant will receive one dose of dexrazoxane. blood samples will be collected to determine the time course and degradation of topoisomerase 2b and topoisomerase 2a

Eligibility criteria:
inclusion criteria: * women, * age 18-65, * not pregnant, not currently breast feeding * no current illness, exclusion criteria: * pregnancy, currently breast feeding * current illness, * history of cardiac, or renal disease

Keywords: dexrazoxane topoisomerase 2b human doxorubicin cardio-toxicity cardio-oncology onco-cardiology prevention of cardio-toxicity by doxorubicin early administration of dexrazoxane
women's assessed cardiovascular evaluation with mcg

Conditions: Ischemia; Cardiac Disease; Risk Factor, Cardiovascular

Summary: cardiovascular disease (cvd) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. research has shown that while hypertension in women is less controlled, they are also less likely to be identified with ischemic heart disease and when diagnosed treated less aggressively than men. moreover, women who are diagnosed with breast cancer have an increased risk for cardiovascular disease. the women's assessed cardiovascular evaluation with mcg (wace-mcg) study is designed to collect cardioflux scans on a select group of female volunteers who are ms. medicine patients. cardioflux is used as a noninvasive mcg tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. there will be a 12-month duration of the study where we propose to collect screening data from approximately 200 volunteers who present to the genetesis facility for a 5-minute cardioflux mcg scan. the volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.


Eligibility criteria:
inclusion criteria: ≥ 18 years of age at the time of enrollment. female patients deemed at risk for cardiovascular disease (breast cancer survivors, patients referred to cardiologists, prior covid-19 patients, etc.) exclusion criteria: \< 18 years of age patients unable to fit into device non-ambulatory patients positive response on cardioflux pre-screening form patients with claustrophobia or unable to lie supine for 5 minutes pregnant women poor candidate for follow-up (e.g. no access to phone) prisoners

Keywords: cardiovascular disease magnetic field map cardioflux ischemia magnetocardiography mcg
mp-3 biofeedback training and central vision loss

Conditions: Age-Related Macular Degeneration

Summary: the objectives of this investigation are: * evaluate the results of rehabilitation treatment using photostimulation with a structured stimulus in two different samples of low vision subjects with central vision loss who will be subjected to biofeedback at the mp3 microperimeter with different timing; * compare the effectiveness of the rehabilitation treatments in the two groups to provide useful indications for proposing standardisation of the rehabilitation pathway focusing on photostimulation in subjects with central vision loss.


Eligibility criteria:
inclusion criteria: * age related macular degeneration exclusion criteria: * cognitive impairment; concomitant eye disease; significant media opacities; ocular surgery within previous 90 days
analysis of a biomarker signature in patients with multiple sclerosis (ms) treated with gilenya (fty720)

Conditions: Multiple Sclerosis

Summary: this study investigates whether there is a link between disease activity/progression in patients receiving gilenya and expression of a putative biomarker signature in patients with multiple sclerosis.

gilenya modulates expression of the sphingosine-1-phosphate receptor and inhibits egress of several lymphocyte subsets from lymph nodes. this results in immunosuppression that has a beneficial effect in patients with multiple sclerosis. our laboratory reported that increased expression of a possible biomarker signature, consisting of tlr2, tlr4 and ccr1, in a t-subset is associated with rapid ms progression. the investigators will test whether a significant proportion of patients at baseline upregulate this biomarker signature in one or more t-subsets, whether expression of this biomarker signature changes with treatment with gilenya and whether expression levels of this signature predict disease activity or progression over a 12 month followup period. the investigators will study patients who are already being treated with gilenya by their neurologists or who are already being treated with gilenya as part of a clinical trial sponsored by novartis pharmaceuticals canada. patients will not be treated with gilenya for the purposes of our study.

Eligibility criteria:
inclusion criteria: * treatment with gilenya exclusion criteria: * subject is under 18 or over 65. * subject has less than 4 weeks of discontinuation with steroid treatment for a relapse. * subject cannot communicate reliably with investigator. * vulnerable subjects exclude, namely patients defined as those without freedom by the law (e.g. prisoners or by administrative decision) or people hospitalized without their consent.

Keywords: biomarker disease progression
phase ii study of dasatinib (bms-354825) for androgen-deprived progressive prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to learn if men with metastatic prostate cancer and rising prostate specific antigen (psa), who have been surgically castrated or are undergoing androgen deprivation with luteinizing hormone releasing hormone (lhrh) treatment, respond to dasatinib. the safety of this treatment will also be studied.


Eligibility criteria:
inclusion criteria: * males, 18 or older * proven advanced prostate cancer * documented metastatic disease * rising psa levels * castrate levels of testosterone exclusion criteria: * symptomatic cns (brain or spinal cord) metastasis * medical condition which may increase the risk of toxicity * any prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer other than primary androgen deprivation agents * unable to take oral medication
porcine acellular dermal matrix for the treatment of localized gingival recessions

Conditions: Gingival Recession

Summary: aim: the aim of this randomized clinical trial is to evaluate the use of the porcine acellular dermal matrix (padm) for the treatment of rt1 localized gingival recessions. material and methods: forthy patients (n=20) with rt1 localized gingival recessions with height ranging from 3 to 5 mm with and at least, 2mm of keratinized tissue width will be selected to participate in the study. patients will be allocated randomly in two treatment groups: coronally advanced flap (caf) or coronally advanced flap associated with the porcine acellular dermal matrix (caf+ padm). the clinical parameters evaluated at the baseline, 6 and 12 months will be: plaque index (ipl); gingival index (gi); relative gingival recession height (rgrh); gingival recession width (grw); probing depth (pd); relative clinical attachment level (rcal); keratinized tissue height (kth); keratinized tissue thickness (ktt); papilla height (ph). evaluations will be made by the professional and the patient regarding dentin hypersensitivity (hd) (schiff and vas scales respectively), aesthetics (res and vas scales, respectively) and patient\&#39;s centered outcomes, through the questionnaire referring to the ohip-14. descriptive statistical analysis will be expressed as mean ± standard deviation (sd), median, quartiles, percentages and confidence intervals (95% ci). to analyze the normality of the residue, the shapiro-wilk test will be performed. then, the wilcoxon test will be applied to compare the periodontal parameters and a quality of life, before and post-treatment. correlations between parameters and dental hypersensitivity will be analyzed through spearman\&#39;s test. key words: gingival recession, root coverage, biomaterial, acellular dermal matrix.


Eligibility criteria:
inclusion criteria: * rt1 localized gingival recessions with height ranging from 3 to 5 mm; * 2mm or more of keratinized tissue width ; * probing depth less than 3mm; * plaque and gingival index less or equal to 20%. exclusion criteria: * smokers; * pregnants; * nursing; * patients with diabetes mellitus or another condition that interfere in the tissue repair * patients who use drugs or medications that interfere in the tissue repair; * allergies to any composition of the devices of the study.
results of patient rated asthma control test in comparison to diary card data

Conditions: Asthma

Summary: the majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. in this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with seretide (salmeterol/fluticasone combination, sfc) 50/250 µg twice daily. the asthma control test (act) will be used to detect differences in the level of asthma control during treatment. the study aims to show a correlation between improvements of act und the level of asthma control which will be reached by the patients. the aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with sfc. we get information about act in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. correlations are expected between the improvements in act, quality of life and asthma control according to the gaining optimal asthma control (goal) criteria.


Eligibility criteria:
inclusion criteria: * diagnosis of asthma * reversibility \>12% after inhalation of 200 µg salbutamol * willingness and ability to complete daily record card on daily basis and to measure morning pef on daily basis * 80% compliance in diary card completion asthma control status: uncontrolled based on the goal criteria exclusion criteria: * change of asthma medication during the last 4 weeks * asthma exacerbation characterized by use of oral corticoids during the last 3 months pretreatment with inhaled corticosteroids more than 500 mcg beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months * upper or lower respiratory tract infection during the run-in period moderate or severe asthma exacerbation during the run-in period * non compliance with use of discus, pef-meter and incomplete diary card data

Keywords: asthma asthma control test seretide
a prediction model of prolonged mechanical ventilation following acute type a aortic dissection surgery

Conditions: Acute Type A Aortic Dissection

Summary: the goal of this observational study is to develop and validate a predictive model for prolonged mechanical ventilation (pmv) following acute type a aortic dissection (ataad) surgery. the main questions it aims to answer are: 1. to validate the predictive performance of the model for pmv after ataad surgery 2. to assess the proportion of pmv among patients undergoing ataad surgery 3. to evaluate the icu length of stay and operative mortality in patients with pmv following ataad surgery


Eligibility criteria:
inclusion criteria: * age ≥18 years; * diagnosis of acute type a aortic dissection (ataad) confirmed by computed tomography angiography and echocardiography; * patients who underwent aortic surgery requiring cardiopulmonary bypass (cpb), were admitted to the surgical intensive care unit (sicu), and received mechanical ventilation. exclusion criteria: * reintubation; * intraoperative death or failure to survive beyond 72 hours postoperatively; * pregnancy; * severe comorbidities (e.g., lung cancer); * missing critical outcome data (e.g., short-term mortality, mechanical ventilation duration, reintubation).

Keywords: acute type a aortic dissection prolonged mechanical ventilation mechanical ventilation time
abemaciclib, palbociclib or dalpiciclib combined with endocrine therapy as first-line treatment in hr positive, her2 negative unresectable or metastatic breast cancer

Conditions: Breast Cancer

Summary: a multi-center, real world study to evaluate the clinical outcomes and safety of abemaciclib, palbociclib or dalpiciclib combined with endocrine therapy as first-line treatment in hr positive, her2 negative unresectable or metastatic breast cancer.


Eligibility criteria:
inclusion criteria: 1. age \>= 18 years old; 2. patients who were diagnosed as hr positive, her2 negative recurrent unresectable (local or regional) or stage iv (m1) breast cancer between june 2020 to october 2023; 3. received cdk4/6 inhibitors(abemaciclib, palbociclib or dalpiciclib) as first-line therapy for at least one cycle; 4. complete medical history was available. exclusion criteria: 1. medical history was incomplete.

Keywords: abemaciclib palbociclib dalpiciclib hr positive her2 negative
study on the carcinogenesis of gα12 in oral cancer, and the treatment of oral cancer using ga12 inhibitor.

Conditions: Carcinogenesis; Oral Cancer

Summary: study on the carcinogenesis of gα12 in oral cancer, and chemopreventive possibility for the treatment of oral cancer using ga12 inhibitor.

to find out if there is prognostic value which to the performance of gα12 of oral cancer in taiwan and provide some reference for future treatment. we anticipate to enroll 40 persons with normal oral mucosa, 65 persons with oral dysplasia and 150 persons with oral cancer and collect the tissue which was stained for pathological sections over a 3 year period. we also collect the blood and saliva samples from patients and the results along with patient-specific information such as tumor phases, tumor size, lymph node metastasis, cancer metastasis, prognosis and betel nut chewing, smoking and drinking habits and other parameters are statistically analyzed.

Eligibility criteria:
inclusion criteria: * dysplasia or cancer of the oral cavity. exclusion criteria: * pregnant woman

Keywords: gα12 oral cancer